Two pivotal trials that did just that were KEYNOTE-522 2 and IMpassion031. “I think the direction of neoadjuvant therapy now is to replace our adjuvant trials with neoadjuvant trials and power them to look at both pathologic complete response and event-free survival,” she added. To this end, neoadjuvant immunotherapy is recommended for all but the smallest triple-negative breast tumors, according to Dr. The shift is now to the neoadjuvant setting, where the impact on long-term outcomes will be greater. The power of this combination approach was first proven in the metastatic setting. ![]() Chemotherapy can further boost the action of immunotherapy by inducing immunomodulatory changes in the tumor microenvironment. Triple-negative tumors seem to be good targets for immunotherapy because of their high mutation rate, expression of PD-L1, and presence of tumor-infiltrating lymphocytes. “It’s particularly important to optimize our therapy while still trying to individualize it,” Dr. 1 The Giants of Cancer Care recognition program celebrates the achievements of experts whose discoveries have propelled the field of oncology forward and established the building blocks for future advances.Īlthough this subtype is heterogeneous, triple-negative breast cancer generally carries a high risk of recurrence within 2 to 3 years. ![]() Rugo, MD, FASCO, Professor of Medicine and Director of Breast Oncology and Clinical Trials Education at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center. This exciting field of breast cancer research was explored at the 2022 Miami Breast Cancer Conference by Giants of Cancer Care ® honoree Hope S. Immunotherapy has become a potential strategy in treating triple-negative breast cancer, though many questions remain to be answered before long-term survival is achieved by all patients.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |